With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.
Compound 30 (100 mg, 0.12 mmol) is dissolved and K2CO3 (230 mg, 1.7 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-BROMOPROPYL)-TRIMETHYLAMMONIUM bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50C during 30 mins and the mixture is heated for 18 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 CM) supported on a steel frit (diameter 3.5 CM). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). After evaporation of solvent from appropriate combined fractions under reduced pressure, the residue is purified by chromatography on a column (2.5 x 40 CM) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol. , upper phase). After removal of solvent under reduced pressure from the eluate, the residue obtained is dissolved in methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). Evaporation of solvent from the eluate gives the product which is dried under high vacuum. 1H-NMR : aH (300MHZ, CD30D) : 0.75-0. 80 (m, 3 H), 1.00-1. 40 (m, 18 H), 1.60- 1.80 (bs, 2 H), 2.25-2. 40 (bs, 6 H), 3.29 (bs, 27 H), 3.40-3. 60 (m, 6 H), 3.90-4. 00 (m, 2 H), 4.05-4. 25 (m, 6 H), 7.10-7. 20,7. 25-7.40, 7.60-7. 80, 7.80-7. 90 (4 x m, 16H), 8.70-9. 00 (bs, 8 H)., 3779-42-8
The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI